Lien vers HAL – inserm-05002753
Lien DOI – 10.1016/S0168-8278(24)01941-X
EASL Congress 2024, Jun 2024, Milan, Italy. 80, pp.S678-S679, 2024, ⟨10.1016/S0168-8278(24)01941-X⟩
The baseline strategy was the current situation where HepB-BD is administrated alongside HepB3. Costs were assessed from the Burkina Faso government’s perspective, including costs of intervention strategies, HBV vaccination with the birth dose (HepB-BD), and care for advanced HBV disease. A deterministic compartmental dynamic model stratified by age, sex, and transmission mode was used. An epidemiological model implemented the strategies from 2024 to 2124, while a cost-effectiveness model included strategy implementation in 2024 with a health impact assessment over a 100-year horizon. The cost-effectiveness threshold was half of 2022 GDP per capita (US$416.5) and the discount rate was 3%. Deterministic and probabilistic sensitivity analyses were conducted.
The Treat All strategy was the optimal strategy to eliminate HBV MTCT as quickly as possible.